Table 3.
Toxicity associations.
| Variable | Incidence | Grade 3/4 hematologic toxicity (%) | p-value | Grade 3/4 non-hematologic toxicity (%) | p-value | Hospitalization | p-value | Dose reduction or discontinuation for toxicity | p-value | Treatment delay | p-value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age | |||||||||||
| 70–74 | 32 | 10 (31) | 1.0 | 11 (34) | 0.62 | 15 (47) | 0.63 | 17 (53) | 0.63 | 12 (38) | 0.62 |
| ≥75 | 38 | 12 (32) | 16 (42) | 15 (39) | 23 (61) | 12 (32) | |||||
| Sex | |||||||||||
| Male | 50 | 15 (30) | 0.78 | 19 (38) | 1.0 | 22 (44) | 0.80 | 30 (60) | 0.59 | 17 (34) | 1.0 |
| Female | 20 | 7 (35) | 8 (40) | 8 (40) | 10 (50) | 7 (35) | |||||
| KPS | |||||||||||
| 80–100 | 45 | 13 (29) | 0.60 | 18 (40) | 0.80 | 18 (40) | 0.62 | 21 (47) | 0.02 | 16 (36) | 0.80 |
| ≤70 | 25 | 9 (36) | 9 (36) | 12 (48) | 19 (76) | 8 (32) | |||||
| Histology1 | |||||||||||
| Adenocarcinoma | 49 | 15 (31) | 0.73 | 19 (39) | 0.50 | 21 (43) | 0.52 | 28 (57) | 1.0 | 17 (35) | 1.0 |
| Squamous | 11 | 4 (36) | 6 (55) | 6 (55) | 6 (55) | 4 (36) | |||||
| Charlson comorbidity index | |||||||||||
| 0–1 | 44 | 12 (27) | 0.43 | 15 (34) | 0.45 | 19 (43) | 1.0 | 25 (57) | 1.0 | 16 (36) | 0.80 |
| ≥2 | 26 | 10 (38) | 12 (46) | 11 (42) | 15 (58) | 8 (31) | |||||
| Brain metastases | |||||||||||
| Yes | 19 | 5 (26) | 0.77 | 9 (47) | 0.41 | 8 (42) | 1.0 | 14 (74) | 0.11 | 7 (37) | 0.78 |
| No | 51 | 17 (33) | 18 (35) | 22 (43) | 26 (51) | 17 (33) | |||||
| Unintended weight loss | |||||||||||
| Yes | 26 | 9 (35) | 0.79 | 7 (27) | 0.14 | 10 (38) | 0.62 | 19 (73) | 0.05 | 9 (35) | 1.0 |
| No | 44 | 13 (30) | 20 (45) | 20 (45) | 21 (48) | 15 (34) | |||||
| Fall history | |||||||||||
| Yes | 10 | 4 (40) | 0.71 | 3 (30) | 0.73 | 2 (20) | 0.17 | 6 (60) | 1.0 | 2 (20) | 0.48 |
| No | 60 | 18 (30) | 24 (40) | 28 (47) | 34 (57) | 22 (37) | |||||
| Albumin | |||||||||||
| <3.5 g/dL | 27 | 4 (15) | 0.02 | 11 (41) | 0.81 | 11 (41) | 0.81 | 18 (67) | 0.22 | 7 (26) | 0.31 |
| ≥3.5 g/dL | 43 | 18 (42) | 16 (37) | 19 (44) | 22 (51) | 17 (40) | |||||
| Anemia | |||||||||||
| Yes | 31 | 14 (45) | 0.04 | 14 (45) | 0.33 | 13 (42) | 1.0 | 20 (65) | 0.33 | 10 (32) | 0.80 |
| No | 39 | 8 (21) | 13 (33) | 17 (44) | 20 (51) | 14 (36) | |||||
| ADLs | |||||||||||
| Dependent | 4 | 3 (75) | 0.09 | 1 (25) | 1.0 | 1 (25) | 0.63 | 4 (100) | 0.13 | 1 (25) | 1.0 |
| Independent | 66 | 19 (29) | 26 (39) | 29 (44) | 36 (55) | 23 (35) | |||||
| IADLs | |||||||||||
| Dependent | 6 | 3 (50) | 0.37 | 1 (17) | 0.39 | 1 (17) | 0.23 | 5 (83) | 0.23 | 1 (17) | 0.66 |
| Independent | 64 | 19 (30) | 26 (41) | 29 (45) | 35 (55) | 23 (36) | |||||
| Chemotherapy | |||||||||||
| Platinum | 45 | 16 (36) | 0.42 | 18 (40) | 0.80 | 22 (49) | 0.21 | 22 (49) | 0.08 | 17 (38) | 0.44 |
| No platinum | 25 | 6 (24) | 9 (36) | 8 (32) | 18 (72) | 7 (28) | |||||
| Doublet chemo | |||||||||||
| Yes | 56 | 20 (36) | 0.20 | 24 (43) | 0.22 | 28 (50) | 0.02 | 29 (52) | 0.08 | 20 (36) | 0.76 |
| No | 14 | 2 (14) | 3 (21) | 2 (14) | 11 (79) | 4 (29) | |||||
1
10 cases that were neither adenocarcinoma nor squamous were excluded from this analysis; the majority of these were poorly differentiated non-small cell carcinoma.